NEJM Evidence Issues Research Articles in February 2024 Edition
March 28, 2024
March 28, 2024
WALTHAM, Massachusetts, March 28 -- NEJM Evidence, a peer-reviewed journal from New England Journal of Medicine Group that says it presents clinical trial design and decision-making, published research articles on the following topics in its February 2024 edition (Vol. 3, No. 2):
Original Articles:
* Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
* Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
Original Articles:
* Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
* Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure